Drugs / 68Ga-DOTATATE Injection
68Ga-DOTATATE Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07119242 | Jan → Nov 2024 overdue | neuroendocrine neoplasm | HTA Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-DOTATATE Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07119242 ↗ |
| Modality | Diagnostic / imaging agent | “Evaluate the Diagnostic Efficacy, Pharmacokinetics and Safety of 68Ga-DOTATATE Injection PET/CT in NETs” NCT07119242 ↗ |
| Route | Intravenous | “intravenously injected with 68Ga-DOTATATE Injection” NCT07119242 ↗ |